“…Some authors suggested that most patients are stratified into high-, intermediate-, and lowrisk groups based on tumor size, tumor invasiveness, nodal status, primary tumor site, and pathological and molecular parameters (PAX-fusion status) [18,19]. In other words, prognosis for RMS depends on primary tumor site, age, completeness of resection, presence and number of metastatic sites, histology, and biology of the tumor cells [18][19][20]. In addition, the overall cure rates have improved significantly thanks to the multimodal therapies, including surgery, radiotherapy, and chemotherapy (with various combinations of vincristine, actinomycin D, cyclophosphamide, etoposide, irinotecan, or ifosfamide).…”